Harvard Bioscience, Inc. (HBIO)
NASDAQ: HBIO · Real-Time Price · USD
6.00
+0.01 (0.17%)
Jul 28, 2026, 2:38 PM EDT - Market open
Harvard Bioscience Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Operating Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | -9.78 | -56.7 | -12.41 | -3.42 | -9.52 | -0.29 |
Depreciation & Amortization | 5.64 | 5.95 | 7.16 | 7 | 7.58 | 7.62 |
Stock-Based Compensation | 1.51 | 1.86 | 4.34 | 5 | 4.41 | 4.17 |
Other Adjustments | 1.4 | 49.96 | 2.28 | 0.85 | -4.03 | -0.05 |
Change in Receivables | -0.97 | -0.93 | 0.97 | 0.81 | 4.78 | -4.29 |
Changes in Inventories | 0.74 | 2.95 | -0.06 | 1.52 | 0.25 | -5.86 |
Changes in Unearned Revenue | 0.08 | -0.16 | -0.7 | 1.14 | -0.9 | 0.51 |
Changes in Other Operating Activities | 3.11 | 3.82 | -0.14 | 1.13 | -1.42 | -0.54 |
Operating Cash Flow | 3.08 | 6.73 | 1.44 | 14.03 | 1.15 | 1.26 |
Operating Cash Flow Growth | 1.92% | 367.29% | -89.73% | 1117.71% | -8.72% | -86.48% |
Investing Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Capital Expenditures | -1.17 | -1.26 | -2.64 | -1.79 | -1.59 | -1.2 |
Purchases of Intangible Assets | -0.63 | -0.61 | -0.62 | -0.52 | - | -0.15 |
Proceeds from Sale of Investments | - | - | 1.92 | - | - | - |
Proceeds from Business Divestments | - | - | - | 0.51 | - | - |
Investing Cash Flow | -1.8 | -1.86 | -1.34 | -1.8 | -1.59 | -1.35 |
Financing Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Long-Term Debt Issued | - | 40 | 8.8 | 4.5 | 7.8 | 4.25 |
Long-Term Debt Repaid | -23.7 | -37.35 | -8.57 | -15.04 | -9.59 | -4.2 |
Net Long-Term Debt Issued (Repaid) | -23.7 | 2.65 | 0.23 | -10.54 | -1.79 | 0.05 |
Issuance of Common Stock | 0.2 | 0.05 | 0.38 | 0.93 | 0.58 | 3.31 |
Repurchase of Common Stock | -0.11 | -0.16 | -0.58 | -2.52 | -1.63 | -3.51 |
Net Common Stock Issued (Repurchased) | 0.09 | -0.11 | -0.2 | -1.59 | -1.05 | -0.2 |
Other Financing Activities | -3.83 | -3.83 | -0.16 | - | - | -0.1 |
Financing Cash Flow | -0.1 | -1.29 | -0.13 | -12.13 | -2.84 | -0.25 |
Net Cash Flow
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Foreign Exchange Rate Adjustments | 0.37 | 0.93 | -0.14 | -0.32 | -0.04 | -0.16 |
Net Cash Flow | 1.55 | 4.51 | -0.18 | -0.23 | -3.31 | -0.5 |
Free Cash Flow
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 1.91 | 5.47 | -1.2 | 12.24 | -0.44 | 0.07 |
Free Cash Flow Growth | 273.78% | - | - | - | - | -99.18% |
FCF Margin | 2.23% | 6.32% | -1.28% | 10.90% | -0.39% | 0.06% |
Free Cash Flow Per Share | 0.43 | 1.23 | -0.28 | 2.89 | -0.11 | 0.02 |
Levered Free Cash Flow | -25.09 | -42.76 | -8.57 | -4.96 | -7.38 | 0.29 |
Unlevered Free Cash Flow | 8.3 | -36.78 | -2.88 | 11.13 | -3.22 | 2.73 |